Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02964481 · ClinicalTrials.gov registry record
Malignant Hyperthermia Registry and Genetic Testing
A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- 64
- Enrollment target
NCT02964481 is a clinical trial that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 64 participants.
The verdict
NCT02964481 was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to to determine the penetrance of known and probable pathogenic variants in genes and the factors that contribute to penetrance in a population of children and adults in the United States exposed to Malignant Hyperthermia (MH) trigger agents.
Interventions
- GENETIC Whole exome sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-08-18 |
| Est. Completion | 2017-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02964481
The ClinicalTrials.gov registry entry for NCT02964481 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Whole exome sequencing is the first listed.
NCT02964481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02964481 about?
NCT02964481 is a clinical study titled "Malignant Hyperthermia Registry and Genetic Testing". The purpose of this study is to to determine the penetrance of known and probable pathogenic variants in genes and the factors that contribute to penetrance in a population of children and adults in the United States exposed to Malignant Hyperthermia (MH) trigger agents.
What is the current status of trial NCT02964481?
This trial is currently terminated. The enrollment target is 64 participants. The study started on 2015-08-18. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT02964481?
The interventions under investigation include: Whole exome sequencing (GENETIC).
Who is sponsoring clinical trial NCT02964481?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.